GlobeNewswire

NRT and Sightline Announce Exclusive Agreement with Kony to Create the Next Generation Digital Platform for the Resort Casino Industry

Dela

Kony's AppPlatform, combined with NRT and Sightline's Respective Technology Offerings, Will Lead the Casino Market Digital Transformation

LAS VEGAS, Oct. 02, 2017 (GLOBE NEWSWIRE) -- NRT Technology Corp. ("NRT") a leading provider of integrated ticket redemption and payment services to global casino operators, and Sightline Payments ("Sightline"), developers of the disruptive Play+ platform that's powering the next generation of cashless and mobile gaming payment solutions, announced today an exclusive agreement with Kony, Inc., the leading enterprise mobility and digital applications company. This combination creates an all-in-one, fully native app that will serve as the foundation platform for all casino operator omni-channel products and services, further reinforcing NRT and Sightline's mutual "Connecting the Guest Experience(TM)" strategy for a worldwide integrated resort casino industry.

"The collaboration with NRT and Sightline will ensure that their casino customers have access to the most advanced digital experiences available today," said Nate Bruce, Business Development & Alliances, Kony, Inc. "The Kony digital AppPlatform is designed to support all of the digital experiences that a casino guest could ever need and demand, today and in the future."

John Dominelli, CEO of NRT, said, "More casino operators are realizing the importance of mobile apps, but are also discovering that deploying, managing, and enabling apps for next generation products and services can be a very painful and unfulfilling endeavor. The gaming industry is filled with suppliers whose mobile systems don't integrate with one another, causing friction and disconnect between operators and their guests.  It is this 'broken' mishmash of mobile systems that Kony, NRT and Sightline have collectively addressed."

Casinos will for the first time have an enterprise mobile platform that will Connect the Guest Experience(TM) for loyalty, commerce, hospitality and gaming experiences.  

"Casino enterprises recognize the importance of a mobile experience for their guests," said Kirk Sanford, Chief Executive Officer of Sightline Payments.  "Unfortunately operators are faced with challenges around user experiences, costs, disparate systems, and management of their app which is stifling their ability to innovate. We think the timing couldn't be better to announce this deal with Kony because operators know that if they fail to innovate quickly they will become irrelevant in this digital era."

Kony's digital AppPlatform and NRT and Sightline's respective technology enhancements will integrate the following:

  • Property information portals and dynamic advertisement engagement
  • Physical and digital payment methods and resort wallets
  • Numerous forms of physical and mobile gaming
  • Social gaming
  • Cardless player loyalty
  • Casino Management Systems
  • Hospitality point of sale and property management systems
  • Experiential features like geofencing, chat bots for voice navigation, facial recognition, beacons, augmented reality, and in-app video for face-to-face experiences

About NRT Sightline

On September 20, 2017, NRT Technology Corp and Sightline Payments announced a merger. Following the closing of the transaction, which remains subject to regulatory approvals, Sightline's CEO and Founder, Kirk Sanford, will assume the role of President and CEO of the combined entity, which will be named NRT Sightline.  NRT's current Founder, President and CEO, John Dominelli, will become Chairman and CTO of NRT Sightline.

Upon regulatory approval and final closing, NRT Sightline(TM) will be the global leader in the design and development of enterprise platforms for the casino industry. Every year NRT and Sightline collectively enable more than 1 billion physical and digital commerce experiences at over 600 casino properties worldwide.  By seamlessly combining technological innovation with strategic partnerships, our companies create the most convenient, reliable, and secure omni-channel payment ecosystems for casino operators and their guests. Our companies have been recognized with numerous industry awards, including the coveted "Most Innovative Gaming Technology Product of the Year" for the Play+(TM) cloud-based cashless funding platform.  Our solutions are used by casinos, lotteries, race and sports, banking & retailers around the world. We operate across 7 countries and have corporate offices in Las Vegas, Toronto, Macau, and Singapore.

About Kony, Inc.

Kony is the fastest growing, cloud-based enterprise application and mobility solutions company, and a recognized industry leader among mobile application development platform (MADP) providers. Kony helps organizations of all sizes drive business ingenuity by rapidly transforming ideas into innovative and secure omni-channel applications. Built on the industry's leading digital platform, Kony provides the most innovative and secure omni-channel applications, with exceptional user experience and app design. Kony's cross-platform, low-code solution also empowers organizations to develop and manage their own apps to better engage with their customers, partners and employees. By seamlessly leveraging and connecting apps to all types of data sources and information, Kony also enables organizations to transform their business processes and gain valuable insight.  Kony was named the first-place winner in CTIA's MobITs Awards in the Mobile Applications, Development & Platforms category and included on the Inc. 500|5000 list of fastest growing private companies in America.

Media Contacts:

Michael Dominelli
VP of Product & Marketing 
mdominelli@nrttech.com 
1(866) 646-5232 x4248 

Kony Media Relations Contact:

Jean Kondo
510-823-4728
jean.kondo@kony.com 




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: NRT Sightline via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Immunicum AB (publ) Announces Upcoming Investor Events in October and November22.10.2018 16:00Pressmeddelande

Press Release 22 October 2018 Immunicum AB (publ) Announces Upcoming Investor Events in October and November Immunicum AB (publ; IMMU.ST) announced today that the Company will participate in and host investor events in October and November. At all events Carlos de Sousa, CEO of Immunicum, and other members of the management team, will provide a corporate presentation and be available for a question and answer session. BioStock Life Science Summit Date: October 25, 2018 Presentation Time: 18.50 Central European Time Venue: Medicon Village, Scheelevägen 2, Building 302-auditorium, Lund, Sweden Registration Link: https://www.eventbrite.com/e/biostock-life-science-summit-tickets-51114333347 Immunicum Investor Event - Gothenburg Date: October 29, 2018 Presentation Time: 17.30 - 20.00 Central European Time Venue: First Hotel G, Nils Ericsonplatsen, 411 03 Gothenburg, Sweden Immunicum Investor Event - Stockholm Date: October 30, 2018 Presentation Time: 17.30 - 20.00 Central European Time Venu

Immunicum AB (publ) meddelar kommande investerarevent under oktober och november22.10.2018 16:00Pressmeddelande

Pressmeddelande 22 oktober 2018 Immunicum AB (publ) meddelar kommande investerarevent under oktober och november Immunicum AB (publ; IMMU.ST) meddelar i dag att bolaget kommer att anordna och delta i investerarträffar under oktober och november. Vid samtliga event kommer Carlos de Sousa, Immunicums VD, och övriga medlemmar av ledningsgruppen, att hålla en presentation av bolaget och vara tillgängliga för att svara på frågor. BioStock Life Science Summit Datum: 25 oktober 2018 Presentationstid: Kl. 18.50 CET Plats: Medicon Village, Scheelevägen 2, byggnad 302 - hörsalen, Lund Länk för registrering: https://www.eventbrite.com/e/biostock-life-science-summit-tickets-51114333347 Immunicums investerarevent - Göteborg Datum: 29 oktober 2018 Presentationstid: Kl. 17.30 - 20.00 CET Plats: First Hotel G, Nils Ericsonplatsen, 411 03, Göteborg Immunicums investerarevent - Stockholm Datum: 30 oktober 2018 Presentationstid: Kl. 17.30 - 20.00 CET Plats: Ingenjörshuset Citykonferensen, Plan 1, Malmski

Immunicum AB (publ) presenterar prekliniska resultat för ilixadencel i kombination med checkpointhämmare och immunaktiverare på 2018 års ESMO-kongress22.10.2018 12:45Pressmeddelande

Pressmeddelande 22 oktober 2018 Immunicum AB (publ) presenterar prekliniska resultat för ilixadencel i kombination med checkpointhämmare och immunaktiverare på 2018 års ESMO-kongress -- Intratumoral behandling med ilixadencel, en cellbaserad, lagringsbar immunaktiverare, ger en synergistisk antitumöreffekt och förstärker effekten av behandling med anti-PD-1 och anti-CD137 i djurmodeller -- Immunicum AB (publ; IMMU.ST) presenterar under 2018 års ESMO kongress (European Society for Medical Oncology) prekliniska resultat som visar en synergistisk anti-tumöreffekt när bolagets ledande produkt ilixadencel ges i kombination med en checkpointhämmare eller immunaktiverare. Resultaten från studien, som presenteras på en poster, visar att intratumoralt administrerat ilixadencel kan förstärka anti-tumörsvar och överlevnad vid behandling med checkpointhämmare eller immunaktiverare. Detta visar på potentialen hos ilixadencel att bli en komplementerande verkningsmekanism till flera olika framtida im

Immunicum AB (publ) Presents Preclinical Results of Ilixadencel in Combination with Checkpoint Inhibitors and Immune Enhancers at ESMO 201822.10.2018 12:45Pressmeddelande

Press Release 22 October 2018 Immunicum AB (publ) Presents Preclinical Results of Ilixadencel in Combination with Checkpoint Inhibitors and Immune Enhancers at ESMO 2018 -- Intratumoral treatment with ilixadencel, an off-the-shelf cell-based immune primer, provides synergistic anti-tumor effect and enhances efficacy of anti-PD-1 and anti-CD137 treatment in animal model -- Immunicum AB (publ; IMMU.ST) announced today the presentation of preclinical results that showed anti-tumor synergy between its lead product ilixadencel and a checkpoint inhibitor or an immune enhancer in a poster at the European Society for Medical Oncology (ESMO) 2018 Congress. The results of the study highlight the ability of intratumoral ilixadencel to enhance anti-tumor response and survival of systemic checkpoint inhibitors (anti-PD-1) or immune enhancers (anti-CD137/4-1BB). This emphasizes the potential for ilixadencel in multiple future immuno-oncology combination strategies by incorporating complementary mech

Karolinska Development's portfolio company OssDsign announces FDA clearance for Cranioplug22.10.2018 09:00Pressmeddelande

STOCKHOLM, October 22, 2018. Karolinska Development's portfolio company OssDsign announces that its latest product Cranioplug has received 510(k) clearance by the FDA, which allows marketing and sales of the product in US. The implant is the first product of its kind in the US market. Cranioplug is an implant used during neurosurgical procedures. The product is intended to cover and plug holes drilled into the skull during surgery and to reattach cranial bone removed during surgery. Cranioplug resorbs and is replaced with bone during the healing process. Anders Lundqvist, CEO of OssDsign, said: "Receiving clearance for Cranioplug is an important step for OssDsign. This motivates us to increase our presence in the US market and continue to build our US organization throughout 2018 and beyond. The regenerative features of OssDsign's calcium phosphate composition are now getting recognized, and it's our mission to turn them into real benefits for patients, surgeons and hospital systems."

Karolinska Development's portfolio company OssDsign announces FDA clearance for Cranioplug22.10.2018 09:00Pressmeddelande

STOCKHOLM, October 22, 2018. Karolinska Development's portfolio company OssDsign announces that its latest product Cranioplug has received 510(k) clearance by the FDA, which allows marketing and sales of the product in US. The implant is the first product of its kind in the US market. Cranioplug is an implant used during neurosurgical procedures. The product is intended to cover and plug holes drilled into the skull during surgery and to reattach cranial bone removed during surgery. Cranioplug resorbs and is replaced with bone during the healing process. Anders Lundqvist, CEO of OssDsign, said: "Receiving clearance for Cranioplug is an important step for OssDsign. This motivates us to increase our presence in the US market and continue to build our US organization throughout 2018 and beyond. The regenerative features of OssDsign's calcium phosphate composition are now getting recognized, and it's our mission to turn them into real benefits for patients, surgeons and hospital systems."

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum